161 results
DEFM14A
AGXRW
Agile Therapeutics Inc
25 Jul 24
Proxy related to merger
6:06am
Statement
Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
Definitive Proxy Statement
Definitive Additional Materials … that apply):
No fee required
Fee paid previously with preliminary materials
Fee computed on table in exhibit required by Item 25(b) per Exchange
8-K/A
EX-10.1
AGXRW
Agile Therapeutics Inc
15 Jul 24
Financial Statements and Exhibits
4:35pm
and 16, and the raw materials ordered on Agile purchase order no. 20102 (the “Secured Obligations”), Agile hereby pledges and grants to Corium a lien … materials used in the Manufacture of the Product on a per Unit basis [***], the Parties will meet to renegotiate the transfer price in good faith for the purpose of sharing the [***] fairly between the Parties.
PREM14A
AGXRW
Agile Therapeutics Inc
12 Jul 24
Preliminary proxy related to merger
5:29pm
Statement
Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
Definitive Proxy Statement
Definitive Additional Materials … that apply):
No fee required
Fee paid previously with preliminary materials
Fee computed on table in exhibit required by Item 25(b) per Exchange
DEFA14A
AGXRW
Agile Therapeutics Inc
26 Jun 24
Additional proxy soliciting materials
8:15am
) a proxy statement on Schedule 14A relating to a special meeting of its stockholders. Additionally, Agile may file other relevant materials with the SEC … materials filed or that will be filed with the SEC, as well as any amendments or supplements to these materials and documents incorporated by reference
8-K
EX-99.1
ccpe46
26 Jun 24
Entry into a Material Definitive Agreement
8:00am
8-K
EX-10.1
p85e 5lobn
26 Jun 24
Entry into a Material Definitive Agreement
8:00am
8-K
EX-2.1
1skccogbvfc c2z4
26 Jun 24
Entry into a Material Definitive Agreement
8:00am
8-K
EX-10.2
aogd6
26 Jun 24
Entry into a Material Definitive Agreement
8:00am
8-K
gql 4h66h81n
26 Jun 24
Entry into a Material Definitive Agreement
8:00am
8-K
4p5d6w9wym
21 May 24
Entry into a Material Definitive Agreement
8:30am
8-K
jh6gcn4 x5
25 Mar 24
Agile Therapeutics Announces Delisting from Nasdaq
4:30pm
8-K
EX-10.1
2a0s8
23 Feb 24
Agile Therapeutics Announces Exercise of Warrants for $4.8 Million Gross Proceeds
4:30pm
8-K
j82cuszx4fadd lm
15 Feb 24
Net Revenue for Full Year 2023 Expected to be in the Range of $20 to $21 Million, an Increase of 84% to 93% Compared to Full Year 2022
4:45pm